» Articles » PMID: 26313650

Separate and Combined Effects of Gabapentin and [INCREMENT]9-tetrahydrocannabinol in Humans Discriminating [INCREMENT]9-tetrahydrocannabinol

Overview
Journal Behav Pharmacol
Date 2015 Aug 28
PMID 26313650
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of the present study was to examine a potential mechanism of action of gabapentin to manage cannabis-use disorders by determining the interoceptive effects of gabapentin in cannabis users discriminating [INCREMENT]-tetrahydrocannabinol ([INCREMENT]-THC) using a pharmacologically selective drug-discrimination procedure. Eight cannabis users learned to discriminate 30 mg oral [INCREMENT]-THC from placebo and then received gabapentin (600 and 1200 mg), [INCREMENT]-THC (5, 15, and 30 mg), and placebo alone and in combination. Self-report, task performance, and physiological measures were also collected. [INCREMENT]-THC served as a discriminative stimulus, produced positive subjective effects, elevated heart rate, and impaired psychomotor performance. Both doses of gabapentin substituted for the [INCREMENT]-THC discriminative stimulus and engendered subjective and performance-impairing effects that overlapped with those of [INCREMENT]-THC when administered alone. When administered concurrently, gabapentin shifted the discriminative-stimulus effects of [INCREMENT]-THC leftward/upward, and combinations of [INCREMENT]-THC and gabapentin generally produced larger effects on cannabinoid-sensitive outcomes relative to [INCREMENT]-THC alone. These results suggest that one mechanism by which gabapentin might facilitate cannabis abstinence is by producing effects that overlap with those of cannabinoids.

Citing Articles

Postmarketing Surveillance of Full Spectrum Hemp Extract CBD Products: Reported Adverse Events and Serious Adverse Events.

Kingsbury C, Zvorsky I, Spelman K Drugs Real World Outcomes. 2024; 11(4):669-678.

PMID: 39340755 PMC: 11589052. DOI: 10.1007/s40801-024-00454-x.


Combining noninvasive brain stimulation with behavioral pharmacology methods to study mechanisms of substance use disorder.

Wesley M, Lile J Front Neurosci. 2023; 17:1150109.

PMID: 37554294 PMC: 10405288. DOI: 10.3389/fnins.2023.1150109.


Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder.

Castillo F, Jones J, Luba R, Mogali S, Foltin R, Evans S Pharmacol Biochem Behav. 2022; 221:173482.

PMID: 36244527 PMC: 10117180. DOI: 10.1016/j.pbb.2022.173482.


Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders.

Prisciandaro J, Mellick W, Squeglia L, Hix S, Arnold L, Tolliver B Addict Biol. 2021; 27(1):e13085.

PMID: 34390300 PMC: 9104469. DOI: 10.1111/adb.13085.


Gabapentin attenuates somatic signs of precipitated THC withdrawal in mice.

Eckard M, Kinsey S Neuropharmacology. 2021; 190:108554.

PMID: 33845073 PMC: 8204917. DOI: 10.1016/j.neuropharm.2021.108554.


References
1.
Petroff O, Hyder F, Rothman D, Mattson R . Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients. Epilepsia. 2000; 41(6):675-80. DOI: 10.1111/j.1528-1157.2000.tb00227.x. View

2.
de-Paris F, SantAnna M, Vianna M, Barichello T, Busnello J, Kapczinski F . Effects of gabapentin on anxiety induced by simulated public speaking. J Psychopharmacol. 2003; 17(2):184-8. DOI: 10.1177/0269881103017002006. View

3.
Mason B, Quello S, Goodell V, Shadan F, Kyle M, Begovic A . Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2013; 174(1):70-7. PMC: 3920987. DOI: 10.1001/jamainternmed.2013.11950. View

4.
Bestard J, Toth C . An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy. Pain Pract. 2010; 11(4):353-68. DOI: 10.1111/j.1533-2500.2010.00427.x. View

5.
Nakano S, GILLESPIE H, Hollister L . A model for evaluation of antianxiety drugs with the use of experimentally induced stress: Comparison of nabilone and diazepam. Clin Pharmacol Ther. 1978; 23(1):54-62. DOI: 10.1002/cpt197823154. View